Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.85) by 4.71 percent. This is a 14.08 percent decrease over losses of $(0.71) per share from the same period last year. The company reported quarterly sales of $1.32 million which beat the analyst consensus estimate of $859.70 thousand by 54.12 percent. This is a 189.93 percent increase over sales of $457.00 thousand the same period last year.